Intraarterially administered abciximab as an adjuvant thrombolytic therapy: report of three cases.
The intravenous administration of abciximab can be used as an adjuvant therapy to facilitate thrombolysis for acute cerebrovascular occlusion. However, to our knowledge, the intraaterial administration of abciximab has not been reported. We recently treated three patients with acute thrombosis of the cerebral arteries by using an intraarterial infusion of urokinase and abciximab. Even with small doses, we achieved rapid and complete recanalization without complications. We believe that the intraarterial infusion of abciximab may be promising for effective and safe recanalization of acute thrombotic occlusion of cerebral arteries.
Kwon
O-Ki
OK
Neurovascular Center, Inje University, Seoul Paik Hospital, Seoul, Korea.
Lee
Ki Jae
KJ
Han
Moon Hee
MH
Oh
Chang-Wan
CW
Han
Dae Hee
DH
Koh
Young Cho
YC
D000077284:Abciximab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D002533:Cerebral Angiography; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D020767:Intracranial Thrombosis / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D000077284:Abciximab